Grace Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 13, 2023 and accepted by EDGAR at Nov 13, 2023, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-07-01 to 2023-09-30 | $460.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-04-01 to 2023-09-30 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-04-01 to 2023-09-30 | −$6.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-07-01 to 2023-09-30 | −$446.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-04-01 to 2023-09-30 | −$735.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-04-01 to 2023-09-30 | −$7.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-04-01 to 2023-09-30 | −$0.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-04-01 to 2023-09-30 | −$0.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 7,552,677 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-04-01 to 2023-09-30 | 7,494,425 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-04-01 to 2023-09-30 | −$8.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $27.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $28.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $78.2m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $1.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $11.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | $66.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-062437. Last ingested by Listed: Oct 26, 2026, 18:07 ET. Listed shows no prices and gives no investment advice.